PreTarg-it® Programs

About OncoOne

OncoOne is a private, preclinical-stage biotech based in Vienna, Austria, pioneering next-generation targeted cancer therapies. The company's core assets are two distinct but complementary technology platforms: the Anti-oxMIF platform targeting a novel tumor-associated form of the macrophage migration inhibitory factor (MIF), and the PreTarg-it® platform, a modular system for pre-targeted radioimmunotherapy designed to enhance precision and safety. Currently seeking Series A+/B financing and strategic partnerships, OncoOne aims to advance its pipeline of highly differentiated candidates into clinical development for oncology and chronic inflammatory diseases.

Therapeutic Areas

Other Oncology (various solid tumors) Drugs